SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

Blood

Volumn 101, Issue 7, 2003, Pages 2784-2788

  Galm, Oliver ^b   Yoshikawa, Hirohide ^b   Esteller, Manel ^b   Osieka, Rainhardt ^b   Herman, James G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTOKINE; INTERLEUKIN 6; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG; CARRIER PROTEIN; DNA BINDING PROTEIN; REPRESSOR PROTEIN; SIGNAL PEPTIDE; SOCS1 PROTEIN, HUMAN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG SENSITIVITY; FEMALE; GENE; GENE INACTIVATION; GENE SILENCING; HEMATOPOIETIC CELL; HISTOLOGY; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOMA; MALE; MULTIPLE MYELOMA; MYELOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SAMPLE; SIGNAL TRANSDUCTION; SOCS 1 GENE; UPREGULATION; CELL CULTURE; FEEDBACK SYSTEM; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BONE MARROW CELLS; CARRIER PROTEINS; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; FEEDBACK, BIOCHEMICAL; FEMALE; GENE SILENCING; HEMATOPOIETIC STEM CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0038784365     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1735     Document Type: Article

References (40)

1. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-872.
2. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
3. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19:2548-2556.
4. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334:297-314.
5. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37:1-11.
6. Alexander WS, Starr R, Metcalf D, et al. Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J Leukoc Biol. 1999;66:588-592.
7. Nicola NA, Greenhalgh CJ. The suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hematol. 2000;28:1105-1112.
8. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-921.
9. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-924.
10. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924-929.
11. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukoc Biol. 2001;70:348-356.
12. Diehl S, Anguita J, Hoffmeyer A, et al. Inhibition of Thl differentiation by IL-6 is mediated by SOCS1. Immunity. 2000;13:805-815.
13. Trop S, De Sepulveda P, Zuniga-Pflucker JC, Rottapel R. Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell receptor-induced proliferation but not differentiation of immature thymocytes. Blood. 2001;97:2269-2277.
14. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29-35.
15. Singal R, Ginder GD. DNA methylation. Blood. 1999;93:4059-4070.
16. Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis. 2000;21:461-467.
17. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10:687-692.
18. Herman JG, Civin CI, Issa JP, et al. Distinct patterns of inactivation of P15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837-841.
19. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999;93:4347-4353.
20. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood. 2000;95:3208-3213.
21. Ng MH, To KW, Lo KW, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res. 2001;7:1724-1729.
22. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood. 2000;95:19-29.
23. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-309.
24. Esteller M, Galdano G, Goodmann SN, et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large cell lymphoma. J Natl Cancer Inst. 2002;94:26-32.
25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
26. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-797.
27. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654-3663.
28. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991;77:587-593.
29. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol. 2000;109:823-828.
30. Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C. Molecular aspects of multiple myeloma. Ann Oncol. 2000;11:1217-1228.
31. Ng MH, Chung YF, Lo KW, et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood. 1997;89:2500-2506.
32. Urashima M, Teoh G, Ogata A, et al. Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res. 1997;3:2173-2179.
33. Tasaka T, Asou H, Munker R, et al. Methylation of the p16INK4A gene in multiple myeloma. Br J Haematol. 1998;101:558-564.
34. Guillerm G, Gyan E, Wolowiec D, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood. 2001;98:244-246.
35. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilllland DG. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol. 2001;21:3547-3557.
36. Rottapel R, Ilangumaran S, Neale C, et al. The tumor suppressor activity of SOCS-1. Oncogene. 2002;21:4351-4362.
37. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103-107.
38. Willemze R, Suclu S, Archimbaud E, et al. A randomized phase II study on the effects of 5-aza-2′deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia. 1997;11 (suppl 1):S24-S27.
39. Wiiermans P, Lubberl M, Verhoef G, et al. Lowdose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
40. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063-3070.